Broadwood Partners, L.P. and its affiliates, which own approximately 27.5% of STAAR Surgical’s outstanding common stock, filed a definitive proxy statement and GREEN proxy card with the U.S. Securities and Exchange Commission on 2025‑09‑24. The filing announces the firm’s intention to vote against the proposed $1.5 billion acquisition of STAAR by Alcon.
The proxy statement includes a letter to fellow shareholders urging them to oppose the merger, citing concerns about the valuation and strategic fit. It also provides the voting instructions for the special meeting scheduled for October 23, 2025, where shareholders will decide the fate of the deal.
Broadwood’s formal opposition intensifies the shareholder battle over the Alcon transaction, potentially delaying or derailing the merger. The move could influence other large shareholders and add uncertainty to STAAR’s future, making it a significant development for investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.